Clinical Trials Browser

Prostatic Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Carcinoma, Transitional Cell

Breast Neoplasms, Triple Negative Breast Neoplasms

Urinary Bladder Neoplasms

Lung Neoplasms, Small Cell Lung Carcinoma

Breast Neoplasms, Triple Negative Breast Neoplasms

Glioblastoma

Carcinoma, Transitional Cell

Carcinoma, Non-Small-Cell Lung

Salivary Gland Neoplasms

Urothelial Bladder Carcinoma

Ovarian Neoplasms

Breast Neoplasms

Cholangiocarcinoma, Klatskin Tumor

Squamous Cell Carcinoma of Head and Neck, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Endometrial Neoplasms

Uterine Cervical Neoplasms

Breast Neoplasms

Breast Neoplasms

Advanced Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Breast Cancer Metastatic

Salivary Gland Neoplasms, Thyroid Neoplasms

Breast Neoplasms

Lung Neoplasms

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Triple Negative Breast Neoplasms

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Esophageal Squamous Cell Carcinoma

HER2-negative Breast Cancer

Thyroid Carcinoma, Anaplastic

Urinary Bladder Neoplasms

Breast Neoplasms

Brain Neoplasms, Breast Neoplasms

Clinical Trials

Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

NeoSTAR

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

ADJUNCT

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

InCITe

Sacituzumab Govitecan in Recurrent Glioblastoma

Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer

TianjinCIH

Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

SATROPIN

STORM

Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

SERIES

First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.

PRIMED

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Scalp Cooling in MBC

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

ALTER

Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer

TROP2

Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy

SG-ESCC

ORIENTA

SETHY

preSAVE

ACROSS-TROP2

Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases